Roche retreats on best-selling Tamiflu

A supermarket chemist in Basel Keystone

The pharmaceuticals giant, Roche, has withdrawn a bid to win approval for sales in Europe of the influenza drug, Tamiflu. It said the body handling the bid had asked for more information, and that it would re-submit the application as soon as possible.

This content was published on May 26, 2000 - 14:56

Roche said several members of the Committee for Proprietary Medicinal Products (CPMP) wanted more detail on one of two influenza viruses, known as Influenza B.

The Basel-based company said it expected to be able to provide the information and submit the bid again before the next wave of influenza in Europe.

Tamiflu is already available in nine countries, including Switzerland, the United States, Canada, and several in Latin America.

The drug has become one of Roche's best-selling products, being used in those markets to treat hundreds of thousands of patients during the last influenza season. Roche is pressing for Tamiflu to be authorised in the US for use as a preventive drug, as well as to treat symptoms.

swissinfo with agencies

This article was automatically imported from our old content management system. If you see any display errors, please let us know:

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Share this story

Change your password

Do you really want to delete your profile?